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Existence of relationship between the level of
sex-steroids and  the risk of cardio-vascular events
has been suspected for years. Men experience
a gradual decrease in testosterone levels from the
age of 30 and onward.
Age and male gender are the strongest inde-
pendent risk factors for coronary artery disease
(CAD). Whilst a wide variation in CAD mortality
exists between countries, a male to female ratio of
approximately 2:1 is consistently observed. Sex
hormones decline with age in both sexes but the
relationship of sex hormones to cardiovascular risk
is complex. Pre-menopausal women have a lower
incidence of CAD, but this rises after menopause
so that the risk rapidly approaches that of males.
One explanation for this phenomenon is that sex
hormones influence the development and progres-
sion of coronary artery disease. These observations
have led to the assumption that testosterone may
exert a damaging influence on the cardiovascular
system. Despite this, coronary atherosclerosis in-
creases with age, while a marked fall in serum
bioavailable testosterone levels is observed. Low testo-
sterone level promote adverse risk factor profile [1].
It was documented that older men with low testo-
sterone level have higher risk of development
impaired glucose tolerance and diabetes in compa-
rison with older men having higher testosterone
concentrations [2]. Some studies demonstrated the
positive association between levels of testosterone
and HDL cholesterol both in male and in female [3].
Other studies show even more univocally results.
In Tromso study men with lowest free testosterone
levels had increased risk of all-cause mortality [4].
On the other hand it is not obvious if testoste-
rone ‘supplementation’ brings positive effects. The
problem in properly caring for ‘low’ testosterone
patients is that we do not yet have definition for
‘normal’ testosterone values at different ages, nor
have we identified specific signs and symptoms to
accurately discriminate between those who need
‘treatment’ and those who do not. Another issue
relates to the health outcomes affected by testoster-
one treatment [5]. If it is decided to correct a man’s
testosterone levels, it should be defined what to
expect from treatment. A meta-analysis of randomi-
zed trials that assessed the effect of testosterone
use on cardiovascular events and risk factors in men
done by Haddad et al. [6] revealed that currently
available evidence weakly supports the conclusion
that testosterone use in men is not associated with
important cardiovascular effects.
Several previous studies documented that plas-
ma levels of both total and bio-available testoste-
rone fell transiently in the first 24 hours after myo-
cardial infarction [7–9]. In addition the pro-fibrin-
olytic activity of testosterone was noted and
a relation with hemostatic factors confirmed by se-
veral subsequent studies of healthy men and subjects
with coronary disease risk factors [10, 11].
In this issue of Cardiology Journal, Militaru et al.
[12] evaluated the association between serum tes-
tosterone levels and 30-day mortality in 126 patients
with acute myocardial infarction. Testosterone le-
vels were significantly lower in 16 patients who died
than in survivors (2.1 ± 0.8 vs 4.3 ± 3.3 ng/mL;
p < 0.001). The authors demonstrated that patients
with lower values of testosterone had higher preva-
lence of diabetes and obesity, higher levels of to-
tal cholesterol and triglycerides but also they had
higher level of HDL cholesterol and lower levels
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of LDL cholesterol. At the same time, they showed
higher level of C-reactive protein (CRP) than pa-
tients with higher levels of testosterone. This ob-
servation might indicate that higher levels of HDL
cholesterol might not be protective in the presence
of ongoing inflammatory process, measured by ele-
vated CRP and in the presence of low testosterone
levels. The association between less protective ef-
fects of HDL cholesterol and testosterone levels
requires further investigations. Despite these dif-
ferences in clinical presentation among patients
with different testosterone levels, evaluated by
quartiles, the authors found that the risk of death
after myocardial infarction was found to be signifi-
cantly associated with lower levels of testosterone
after adjustment for imbalances in clinical covari-
ates. The word of caution has to be expressed re-
garding a possibility that a presence of prior myo-
cardial infarction and heart failure, factors known
to be associated with lower testosterone levels,
might have contributed to lower testosterone le-
vels in non-survivors. Nevertheless, since ejection
fraction and brain natriuretic peptide levels did not
show meaningful differences, one could assume that
these factors were of lesser influence in studied
population.
These important observations made by Milita-
ru et al. [12], based on relatively small study popu-
lation, require further proof in larger cohorts. How-
ever, these findings are encouraging to further eva-
luate the role of testosterone levels in the setting
of acute coronary syndromes with potential reper-
cussions regarding possible treatment of patients
with low testosterone levels.
References
1. Phillips GB, Pinkernell BH, Jing TY. Are major risk factors for
myocardial infarction the major predictors of degree of coronary
artery disease in men? Metabolism, 2004; 53: 324–329.
2. Freedman DS, O’Brien TR, Flanders WD, DeStefano F, Barbo-
riak JJ. Relation of serum testosterone levels to high density
lipoprotein cholesterol and other characteristics in men. Arte-
rioscler Thromb, 1991; 11: 307–315.
3. Wranicz JK, Cygankiewicz I, Rosiak M, Kula P, Kula K, Zareba W.
The relationship between sex hormones and lipid profile in men
with coronary artery disease.  Int J Cardiol, 2005; 101: 105–110.
4. Vikan T, Schirmer H, Njolstad I, Svartberg J. Endogenous sex
hormones and the prospective association with cardiovascular
disease and mortality in men: The Tromso Study. Eur J Endo-
crinol, 2009; 161: 435–442.
5. Isidori AM, Lenzi A. Testosterone replacement therapy: What
we know is not yet enough. Mayo Clin Proc, 2007; 82: 11–13.
6. Haddad RM, Kennedy CC, Caples SM et al. Testosterone and
cardiovascular risk in men: A systematic review and meta-analysis
of randomized placebo-controlled trials. Mayo Clin Proc, 2007;
82: 29–39.
7. Glueck CJ, Glueck HI, Stroop D, Speirs J, Hamer T, Tracy T.
Endogenous testosterone, fibrinolysis, and coronary heart disease
risk in hyperlipidemic men. J Lab Clin Med, 1993; 122: 412–420.
8. Tripathi Y, Hegde BM. Serum estradiol and testosterone levels
following acute myocardial infarction in men. Indian J Physiol
Pharmacol, 1998; 42: 291–294.
9. Pugh PJ, Channer KS, Parry H, Downes T, Jone TH. Bio-avail-
able testosterone levels fall acutely following myocardial infarc-
tion in men: Association with fibrinolytic factors. Endocr Res,
2002; 28: 161–173.
10. Caron P, Bennet A, Camare R, Louvet JP, Boneu B, Sie P. Plas-
minogen activator inhibitor in plasma is related to testosterone
in men. Metabolism, 1989; 38: 1010–1015.
11. De Pergola G, De MV, Sciaraffia M et al. Lower androgenicity is
associated with higher plasma levels of prothrombotic factors
irrespective of age, obesity, body fat distribution, and related
metabolic parameters in men. Metabolism, 1997; 46: 1287–1293.
12. Militaru C, Donoiu I, Dracea O, Ionescu D-D. Serum testoste-
rone and short-term mortality in men with acute myocardial
infarction. Cardiol J, 2010; 17: 249–253.
